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Abstract
We propose a curve-based Riemannian-geometric approach for general shape-
based statistical analyses of tumors obtained from radiologic images. A key com-
ponent of the framework is a suitable metric that (1) enables comparisons of tumor
shapes, (2) provides tools for computing descriptive statistics and implementing prin-
cipal component analysis on the space of tumor shapes, and (3) allows for a rich class
of continuous deformations of a tumor shape. The utility of the framework is illus-
trated through specific statistical tasks on a dataset of radiologic images of patients
diagnosed with glioblastoma multiforme, a malignant brain tumor with poor prog-
nosis. In particular, our analysis discovers two patient clusters with very different
survival, subtype and genomic characteristics. Furthermore, it is demonstrated that
adding tumor shape information into survival models containing clinical and genomic
variables results in a significant increase in predictive power.
Keywords: Magnetic resonance imaging; Shape manifold; Glioblastoma multiforme; Clus-
tering; Survival analysis.
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1 Introduction
1.1 Radiological imaging in cancer
There is intensive worldwide interest in preventing, detecting and treating cancer. Ra-
diologic tools for detecting and treating cancer play central roles in disease management
and surveillance. Technological advances in imaging equipment and techniques, and de-
velopment of stage-specific methods for cancer, make medical imaging an indispensable
tool for clinicians to monitor and stage various cancers (Gutman et al., 2013). Clinical
decision-making, particularly for the brain, is routinely made on the basis of radiological
image-based features in a magnetic resonance image (MRI). There are three main analyt-
ical tasks in such settings: (1) extraction or segmentation of the tumor region from the
MRI, (2) characterization of the tumor via its shape, volume or other features, and (3)
development of prognostic or predictive (survival time) models that link MRI features with
genomic and clinical variables. Each task brings its own set of challenges.
In this article, we focus primarily on the latter two tasks. Brain tumor characterization
is not straightforward because the tissue surrounding the tumor is often heterogeneous
in spatial and imaging profiles (Krabbe et al., 1997), and sometimes overlaps with normal
tissues (Provenzale et al., 2006). For example, it is extremely difficult to distinguish between
primary central nervous system lymphoma and high-grade glioma using MRI (Liu et al.,
2011). Integrating volumetric and morphological features of tumors obtained from MRI
with clinical and genomic variables is usually based on non-objective numerical summaries
of the features generated by experts. Thus, it is difficult to ascertain the reliability and
reproducibility of such studies, to generalize to different clinical settings.
The biological process governing tumor growth generates artifacts that can assist in the
tasks described above. A tumor normally originates from a single cell, and as it prolifer-
ates in size, it exhibits heterogeneity in physiological and shape-related features (Marusyk
2
et al., 2012). Both inter- and intra-tumor heterogeneity are critical for characterizing
tumors (De Sousa et al., 2013). Inter-patient tumor heterogeneity can be quantified by
morphological characteristics such as the shape and size of the tumor (McLendon et al.,
2008), in addition to the genomics and clinical characteristics of a patient.
The relevance of tumor shape in characterizing tumor heterogeneity is linked to its
growth process. Intrinsic brain tumors tend to evolve along tracts of white matter, al-
tering the tracts in complex ways that include infiltration, displacement and disruption
(Goldberg-Zimring et al., 2005). It is conceivable that new insight into patterns of tumor
growth and invasion in the brain can be obtained through a better understanding of the
shape and evolution of the tumor. Tumor shape is significantly influenced by the location in
the brain and other anatomical constraints—in some places it might infiltrate and in others
displace the fiber tracts. Irregular or spiculated shapes suggest an anisotropic structure
of the underlying white matter; spherical or regular shapes imply a lack of structural or
anatomical restrictions. The size of the tumor evidently affects its shape, especially in the
presence of anatomical restrictions. It is reasonable to theorize that a better understanding
of the relationship between the tumor’s shape and size, and histopathological factors re-
lated to the brain tumor would enhance the understanding of the tumor’s biological growth
process; this would not only enable better prognosis but also potentially predict the like-
lihood of therapeutic success. For example, Figure 1 of our motivating dataset shows two
semi-automated segmentations of T2-weighted fluid-attenuated inversion recovery (FLAIR)
brain-axial MRI of patients diagnosed with glioblastoma multiforme (GBM), also known as
grade IV glioma, with survival times of longer than 50 months (left) and shorter than one
month (right), respectively. The tumor shape for the patient with longer survival appears
to be more regular or spherical than the irregular one corresponding to the patient with a
short survival; the tumor sizes appear to be quite different as well. Evidently, the tumor
locations for the two patients are different, which influences both size and shape.
While the potential importance of tumor shape as a prognostic biomarker has been rec-
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Figure 1: T2-weighted FLAIR MR images of two patients diagnosed with GBM, with survival times
longer than 50 months (left) and shorter than one month (right). The segmented tumor is denoted by the
red outline.
ognized (Goldberg-Zimring et al., 2005; McLendon et al., 2008), there is a striking paucity
of progress in this direction. This is primarily due to the difficulty of representing and inte-
grating tumor shape into existing statistical models. Current approaches that incorporate
the information of a segmented brain tumor’s shape and size into models for tumor char-
acterization and classification are based on subjective features provided by experts such as
tumor circularity/sphericity and irregularity, and numerical summaries such as surface-to-
volume ratio, total tumor area and entropy of the radial distribution of boundary pixels
(Krabbe et al., 1997). Such radiological features are only indicative of tumor shape and
do not fully characterize the shape. Furthermore, the subjective nature of the features
ensures that statistical inference founded on them will suffer from a lack of reproducibility
and reliability. In a recent article exploring the predictive power of MRI features in the
context of GBM, Gutman et al. (2013) state that (page 568):
“...it is often challenging to extract objective information for scientific analysis
from prose statements of imaging features by neuroradiologists who typically use
idiosyncratic vocabulary.”
Gutman et al. (2013) used various measures of agreement of ordinal and numerical values
of neuroimaging features such as size and percentage of necrosis suggested by three expert
radiologists, and noted that volumetric and morphological information of the GBM tumor
is informative for characterizing its biological growth process.
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1.2 Statistical challenges and contributions
We can circumvent issues associated with qualitative and quantitative summaries of tumor
shape by quantifying and utilizing information about the entire tumor shape. This exten-
sion, however, is not straightforward. Viewed statistically, tumor shape is a non-Euclidean
object residing on (a quotient space of) some nonlinear manifold. Thus, appropriate repre-
sentation of a tumor shape should naturally employ statistical methods for non-Euclidean
data objects. Motivated by this need, we focus on examining the utility of the 2D shape of
GBM tumors obtained from a single brain axial imaging slice with the largest tumor area
in two contexts: (1) for detection of inter-tumor heterogeneity, and (2) for evaluation of
its association with molecular (genomic) profiles and survival times of patients diagnosed
with GBM. The methods we employ are broadly applicable to various tumor types. Recent
studies of scalar on image regression models in neuroimaging data applications incorpo-
rated the entire image (Reiss and Ogden, 2010; Jiang and Ogden, 2010; Goldsmith et al.,
2013; Li et al., 2015; Reiss et al., 2011; Huang et al., 2013); such methods are not applicable
in the current setting for the following reasons: (1) the tumors grow and are located in dif-
ferent parts of the brain, (2) the whole-brain images contain a lot of additional information
about other brain structures, which might not be directly related to tumor morphology,
and (3) there is no standard template to which each tumor image can be registered to make
population-level analyses conformable across patients. Thus, our work is distinguished by
its focus on the shape of the tumor only.
We model the 2D tumor shapes as properties of parametric curves in R2, which pro-
vides the flexibility to accommodate uncertainty regarding landmarks and other curve fea-
tures. Broadly speaking, parameterized curves representing tumor shapes can be viewed
as functions defined on a suitable domain; this allows for viewing the tumor shape as a
functional observation, making available a broad array of existing tools from functional
data analysis. However, we show that the space of these curves cannot be modeled as a
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linear vector space (e.g., Hilbert space of square integrable functions), as is usually as-
sumed in these techniques; it is hence not possible to directly use basis representations of
the tumor shapes. Parametric curves representing tumor shapes are viewed as points on an
infinite-dimensional nonlinear manifold, and the statistical methods developed have to be
compatible with the constraints posed by such spaces. We adapt the geometric framework
for the statistical shape analysis of closed curves proposed by Srivastava et al. (2011) for
this purpose. In summary, our main contributions are:
(i) We represent tumors as parameterized, planar, closed curves given by their outlines
in 2D MRIs, and define a suitable shape space that captures relevant information
pertaining to the tumor shapes.
(ii) We define notions of a geodesic path and distance between two tumor shapes, and
an average tumor shape; we also describe methods to perform shape-based principal
component analysis (sPCA) on the tumor shape space and to identify and visualize
principal directions of variation in a sample of tumor shapes.
(iii) On the GBM application (Section 3.1), we illustrate the utility of the developed tools
in clustering and classifying tumor shapes, and inferential tasks such as two-sample
testing (tumor shape heterogeneity detection) and survival time modeling (prognostic
and prognostic capabilities of tumor shape). These tasks are examined in the presence
of genomic and clinical covariates, from which we assess the predictive capabilities of
the proposed representation in terms of patient survival times.
We develop of a coherent statistical representation of the tumor shape, and use the ge-
ometric framework to assist us in implementing supervised and unsupervised tasks such
as clustering and integrating tumor shape as a potential predictive or prognostic factor in
statistical models commonly used in oncology studies. We find the motivation in the GBM
dataset, for which issues about the use of MR imaging features have been recognized but
not satisfactorily addressed. We examine statistical methods to integrate the tumor shape
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with genomic and clinical features of GBM, and investigate associations between them;
this can subsequently accelerate effective personalized therapeutic strategies for cancer de-
velopment and progression. Note that the presented method is more general and can be
applied to other cancers and imaging modalities as well.
The rest of this paper is organized as follows. In Section 2, we provide statistical
tools for analyzing tumor shapes under an elastic framework. In particular, we focus on
comparing and averaging tumor shapes, and summarizing shape variability in a sample
of tumors. Section 3 considers specific statistical tasks on the GBM dataset including
clustering, hypothesis testing and survival modeling. Section 4 provides a short discussion
and directions for future work.
2 Quantifying and visualizing variability in tumor shapes: A ge-
ometric approach
Some issues associated with characterizing tumors in MRIs can be alleviated through a suit-
able representation, which should be versatile enough to accommodate various subjective
evaluations by neuroradiologists, and at the same time, be mathematically and statistically
well-defined so as to facilitate various inferential tasks. Shape analysis based on landmarks
(finite collection of ordered points) (Dryden and Mardia, 1998) is not flexible enough in
this context since the tumors rarely possess landmark features as such. Even if present,
identifying tumor landmarks is difficult, may require subjective assessment, and may not
correspond between tumors from different patients. A natural way to represent a tumor is
to use a 2D curve that corresponds to its boundary or outline. This allows for uncertainty
in all landmark locations, and offers a visually appealing representation.
We adopt and suitably customize the shape definition of Srivastava et al. (2011) that is
particularly attractive in the current context (see (Joshi et al., 2007a,b), (Srivastava et al.,
2011), and (Kurtek et al., 2012) for details). While describing the tools, we concurrently
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(a) (b) (c)
T1 T2 T1 T2 T1 T2
(1)
(2)
Figure 2: Three examples of manually segmented tumor contours overlaid on the T1-weighted post-
contrast (T1) and T2-weighted FLAIR (T2) images for patients with (a) short survival (<1 month), (b)
medium survival (≈15 months) and (c) long survival (> 50 months).
illustrate their usage on the GBM dataset. To get an idea of this problem’s complexity,
we display a few examples of tumor contours overlaid on the corresponding T1-weighted
post-contrast and T2-weighted FLAIR MRI slices in Figure 2. The tumor shapes are
heterogeneous and at first glance, it is difficult to ascertain any relationship between tumor
shapes and survival times. To obtain insight into possible relationships between tumor
shapes and outcomes, more sophisticated approaches are required.
2.1 Representation of tumor shape and elastic metric
The tumor shapes should be invariant to translation and rotation. Scaling might be con-
sidered important, and can easily be incorporated into our framework. Denote a parame-
terized, planar, closed curve representing the outline of a tumor by a function β : S1 → R2.
Since the tumor outline is a closed curve, it is natural to parameterize it using the domain
S1, instead of an interval. There are several possibilities for representing β for the purpose
of shape analysis. One can simply use the x and y coordinate functions of β; another
possibility is to parameterize β using the arc length and compute the angle β˙ = dβ
dt
makes
with the x-axis (here, t is the curve parameter) (Klassen and Srivastava, 2006).
The choice of a metric on the tumor shape space is vital for comparing two shapes.
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Unlike typical problems in shape analysis, there is no template shape available while con-
sidering tumors. In this context, it is imperative that the metric capture and be based on
all possible deformations or transformations that match one tumor shape to another. One
candidate metric is the elastic metric, defined as follows. Suppose p(t) = |β˙(t)| is the speed
function and θ(t) = β˙/|β˙(t)| is the angle function. Consider two tangent vectors (small
perturbations) (δpi, δθi), i = 1, 2 in the tangent space of (p, θ). The elastic metric (Mio
et al., 2007) is defined as:
〈(δp1, δθ1), (δp2, δθ2)〉(p,θ) = a
∫
S1
δp1(t)δp2(t)1/p(t)dt+ b
∫
S1
〈δθ1(t), δθ2(t)〉p(t)dt, (1)
for constants a, b > 0. The first term in Equation (1) measures variations in the speed
function (i.e., how fast the tumor outline is traversed), while the second term measures
the variation in the direction of the unit tangent vectors; a and b provide the relative
weights for the two terms. In other words, the first term captures the amount of stretching
and the second term captures the amount of bending required to deform one tumor shape
into another. Both terms are needed to preserve the geometric properties and natural
deformations between tumor shapes; we explicitly show this in Section 2.2.3 via tumor
shape reconstruction errors. However, choosing a and b is hard and problem-dependent.
An important source of variation is the choice of parameterization of the tumor contours.
This is a nuisance parameter when comparing tumor shapes, since the choice of parameteri-
zation is arbitrary and shape preserving, i.e., the tumor contour can be re-parameterized in
many different ways, but it’s shape remains unchanged. A common approach in the shape
analysis literature is to normalize curve parameterizations to arc length to ensure that
traversal along the curve is at unit speed. Under this scenario, only bending deformations
are allowed, which often results in suboptimal point correspondences across shapes (Mio
et al., 2007). We describe how it is possible to not only profitably employ the elastic metric,
but also ensure that the resulting geodesic distance is invariant to the choice of parameter-
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ization. Unless otherwise stated, all curves representing tumor shapes are parameterized
according to their arc lengths.
2.1.1 Square-root velocity function
Let Γ = {γ : S1 → S1|γ is an orientation-preserving diffeomorphism} be the group of repa-
rameterization functions, and orientation imply clockwise or counter-clockwise traversal of
the contour. The reparameterization of a tumor curve β, termed the action of Γ on the
space of curves, is given by the composition (β, γ) = β ◦ γ. The chief issue with using
the popular L2 metric is that the distance between two tumor contours β1 and β2 is not
preserved under the action of Γ: ‖β1−β2‖ 6= ‖β1◦γ−β2◦γ‖ for a general γ ∈ Γ, where ‖·‖
is the L2 metric for functions on S1. In other words, the action of Γ on the space of tumor
curves is not isometric, which means that a comparison of two tumor shapes depends on
their parameterizations.
A proposed solution (Joshi et al., 2007a,b; Srivastava et al., 2011; Kurtek et al., 2012) is
to use a different representation of curves called the square-root velocity function (SRVF),
given by q(t) = β˙(t)√
|β˙(t)|
, where | · | is the standard Euclidean norm in R2. This representa-
tion is convenient because it is automatically translation invariant. Conversely, β can be
reconstructed from q up to a translation. If a tumor curve β is reparameterized to β ◦ γ,
then its SRVF changes from q to (q, γ) = (q ◦ γ)√γ˙.
The main reasons for using the SRVF for tumor shape analysis are as follows.
(i) The complicated but desirable elastic metric reduces to the standard L2 metric with
a = 1/4 and b = 1, allowing for both bending and stretching of tumor shapes: if δq1
and δq2 are two tangent vectors to the SRVF q of a tumor curve β = (p, θ), then
〈〈δq1, δq2〉〉 = 1
4
∫
S1
δp1(t)δp2(t)1/p(t)dt+
∫
S1
〈δθ1(t), δθ2(t)〉p(t)dt,
where 〈〈·, ·〉〉 is the standard L2 inner product (defined later).
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(ii) ‖q1 − q2‖ = ‖(q1, γ) − (q2, γ)‖, for all γ ∈ Γ, thus allowing for parameterization
invariant analysis of tumor shapes.
If invariance to scale is required, each tumor shape can be re-scaled to unit length. After
re-scaling, ‖q‖2 = ∫S1 |q(t)|2dt = ∫S1 |β˙(t)|dt = 1, i.e., the representation space of all SRVFs
is a Hilbert sphere. For tumor shapes, the scale or size of the tumor is often important,
and the variability in tumor shape due to scale differences is considered to be important
as well. In the GBM data example, we decouple tumor shape and size and consider them
individually as covariates in the survival models. For a closed curve, which characterizes the
tumor contours we are studying, the corresponding SRVF satisfies the additional closure
condition
∫
S1 q(t)|q(t)|dt = 0. Thus, the space of all unit length, planar, closed tumor
curves, represented by their SRVFs, is given by
C =
{
q : S1 → R2|
∫
S1
|q(t)|2dt = 1,
∫
S1
q(t)|q(t)|dt = 0
}
.
2.1.2 Geodesic paths and distances in the elastic shape space
In the absence of a template tumor shape, it is critical to be able to visualize deformations
or changes in tumor shape. The choice of the elastic metric and the SRVF of two tumor
shapes makes it possible to compute natural geodesic paths and distances between them;
as a consequence, we can visually examine the meaningful deformations of one tumor shape
that transforms it into the other by traversing the geodesic path. This is potentially useful
to radiologists for assessing possible changes in tumor morphology, thereby facilitating
targeted interventions. Figure 3 illustrates this with a simulated example, and Figure 4
offers illustrations on the GBM dataset.
Pre-shape space C with parameterization and rotation variability : The pre-shape space C is
a nonlinear submanifold of the Hilbert sphere due to the closure condition. It becomes a
Riemannian manifold with the standard L2 metric, 〈〈v1, v2〉〉 =
∫
S1 〈v1(t), v2(t)〉 dt, where
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v1, v2 ∈ Tq(C) and the inner product in the integrand is the standard Euclidean inner
product in R2. The task of computing geodesic paths between any two elements q1, q2 ∈
C is accomplished numerically, using an algorithm called path straightening, introduced
by Klassen and Srivastava (2006) and adapted to the SRVF representation by Srivastava
et al. (2011). This algorithm initializes a path in C connecting q1 and q2, and iteratively
‘straightens’ it until it becomes a geodesic. Let α∗ : [0, 1]→ C denote the resulting geodesic
path. Then, the length of this geodesic path provides a geodesic distance between q1 and
q2 in C:
dC(q1, q2) = L[α∗] =
∫ 1
0
〈〈α˙∗(τ), α˙∗(τ)〉〉1/2 d τ.
The issue with dC is that it contains contributions from two nuisance sources of variation:
(i) It is a non-zero distance between two tumor shapes when one is just a rotation of the
other;
(ii) It is a non-zero distance between two tumor shapes when one has been obtained
through a reparameterization of the other; since we start with arc length parameter-
ized tumor curves, this distance does not capture stretching deformations that pertain
to the first term of the elastic metric in Equation (1).
Shape space S accounting for parameterization and rotation variability : To remedy the is-
sues with the pre-shape geodesic distance dC between two tumor shapes, it needs to be
computed while accounting for (i) all possible rotations and (ii) all possible reparameter-
izations of one tumor shape to optimally register it to the other. This is achieved in the
following manner.
Let SO(2) be the group of 2×2 rotation matrices (special orthogonal group). For an arc
length parameterized tumor contour β and a rotation O ∈ SO(2), the transformed SRVF
of β is given by Oq. Thus, in order to unify all elements in C that denote the same tumor
shape, we define equivalence classes of the type [q] = {O(q ◦ γ)√γ˙|O ∈ SO(2), γ ∈ Γ}.
Each such equivalence class [q] is associated with a unique tumor shape and vice versa.
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The set of all equivalence classes is called the shape space S and is the quotient space
C/(SO(2)×Γ). The distance dC can be used to define a distance between tumor shapes on
S according to
dS([q1], [q2]) = inf
O∈SO(2), γ∈Γ
dC(q1, (Oq2, γ)).
The geodesic distance dS is now the elastic distance on the space of tumor shapes and is
invariant to rotation and reparameterization; as a consequence, all possible deformations
pertaining to stretching and bending of tumor shapes are captured. Moreover, dS is bounded
above by pi/2, thereby offering a natural scale for comparing tumor shapes. In practice, the
minimization in the definition of dS is performed by sampling each curve with a large
number of points, and then recursively applying singular value decomposition (SVD) to
find the optimal rotation and the dynamic programming algorithm with an additional seed
search to find the optimal reparameterization.
Illustrative examples : We present multiple simulated and real data examples comparing
nonelastic geodesic paths and distances (we only optimize over rotations and the seed
placement but not the full reparameterization group) to the proposed elastic versions com-
puted in the shape space. The points along the geodesic path between two tumor shapes
should be viewed as the possible deformations transforming one tumor shape into the other.
Since, in contrast to elastic shape analysis, the nonelastic framework does not allow stretch-
ing and compression deformations, we observe some unnatural shapes appearing along the
geodesic paths in that case.
We first illustrate our approach on two simulated curves that are ‘toy’ tumor shapes.
The curves were generated so as to reflect the protrusion-type behavior of real GBM tumors,
and were both initially parameterized with respect to their arc lengths. This example is
shown in Figure 3. First, with the given arc length parameterizations, the geometric
features on the two curves do not match. This can be seen from the four colored points.
Panel (a) shows the first simulated tumor outline where the green, black and cyan points
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(a) (b) (c)
Nonelastic geodesic path and distance
dNE = 0.9249
Elastic geodesic path and distance
dS = 0.4709
Figure 3: Comparison of two simulated tumor shapes. (a) Curve with three protruding peaks. (b)
Curve with two protruding peaks before reparameterization (uniform spacing of points). (c) Same as
(b) after reparameterization (optimal non-uniform spacing of points). We show four colored points of
correspondence for improved visualization. The resulting geodesic paths were sampled uniformly using
seven points (NE=nonelastic).
correspond to three peaks. Panel (b) shows the second tumor shape, where the green
point corresponds to a peak while the other two do not. This results in an unnatural
nonelastic geodesic deformation between these two surfaces, where two of the peaks on
the first shape are distorted to form the second peak on the second shape; the resulting
distance is dNE = 0.9249. Under the elastic framework on the shape space S, the optimal
reparameterization is able to match the first two peaks across the two curves very well
(green and black points). Of course, there is no counterpart to the third peak on the
second curve (cyan point). This results in a natural deformation where the two matched
peaks are preserved along the geodesic path while the third one simply grows; the resulting
distance is dS = 0.4709 (nearly a 50% decrease). We hypothesize that improvements such as
the one in this simulated example are extremely important in capturing natural variability
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(a) (b) (c) (d) (e) (f)
Nonelastic geodesic path and distance Nonelastic geodesic path and distance
dNE = 0.9946 dNE = 0.5324
Elastic Geodesic path and distance Elastic geodesic path and distance
dS = 0.5324 dS = 0.4242
Figure 4: Left: Comparison of T1-weighted post-contrast images of tumor shapes for a patient with
survival time of 14.3 months and for a patient with survival time of 29.2 months. Right: Comparison of
T1-weighted post-contrast images of tumor shapes for a patient with a short survival time (8.8 months)
and for a patient with a long survival time (48.6 months). (a)&(d) Curve representing first tumor. (b)&(e)
Curve representing second tumor before reparameterization (uniform spacing of points). (c)&(f) Same as
(b)&(e) after reparameterization (optimal non-uniform spacing of points). We show four colored points
of correspondence for improved visualization. The resulting geodesic paths were sampled uniformly using
seven points (NE=nonelastic).
in GBM tumor shapes. Upon visual inspection, the observed tumor contours have many
geometric structures such as the peaks in this example. This motivates the use of the
elastic shape analysis framework for studying GBM tumors.
Next, we illustrate the elastic representation, alignment, and computation of geodesic
paths and distances between GBM tumor shapes corresponding to patients with different
survival times; Figure 4 presents two examples for the T1-weighted post-contrast modality,
whereas Figure 5 considers the T2-weighted FLAIR modality. In all examples, we have
marked four corresponding points in red, green, black and cyan, and show the stretching
and compression of points along the tumor curve due to optimization over Γ. The geodesic
distances between the tumor shapes (from both T1-weighted post-contrast and T2-weighted
FLAIR images) obtained using dNE and dS are significantly different. The benefit of
using the elastic framework becomes apparent when computing and visualizing geodesic
paths between the tumor shapes: the points along the path represent tumor shapes that
15
(a) (b) (c) (d) (e) (f)
Nonelastic geodesic path and distance Nonelastic geodesic path and distance
dNE = 1.1209 dNE = 1.0113
Elastic Geodesic path and distance Elastic geodesic path and distance
dS = 0.6024 dS = 0.5346
Figure 5: Left: Comparison of T2-weighted FLAIR images of tumor shapes for a patient with survival
time of 2.69 months and for a patient with survival time of 13.3 months. Right: Comparison of T2-
weighted FLAIR images of tumor shapes for a patient with survival time of 6.14 months and for a patient
with survival time of 0.72 months. (a)&(d) Curve representing first tumor. (b)&(e) Curve represent-
ing second tumor before reparameterization (uniform spacing of points). (c)&(f) Same as (b)&(e) after
reparameterization (optimal non-uniform spacing of points). We show four colored points of correspon-
dence for improved visualization. The resulting geodesic paths were sampled uniformly using seven points
(NE=nonelastic).
are elastically deformed in a natural way and preserve important shape features of the
tumors. Indeed, when we allow non-uniform spacing of points along the curves, the geodesic
deformation is improved due to an improved matching of geometric features across the
tumor shapes. For example, for the T1-weighted post-contrast example in the left portion
of Figure 4, the deformations along the geodesic path defined through the distance dS
are natural in the following sense: the highly concave geometric feature of both tumors is
nicely preserved along the geodesic path; this is not true in the nonelastic case. At the same
time, other local geometric features in the form of concave and convex curve segments are
preserved along the elastic shape geodesic. This is also clearly evident in the two examples
shown for the T2-weighted FLAIR modality in Figure 5. It is important to note that these
geodesic path improvements are accompanied by significant distance reductions between
the nonelastic and elastic frameworks; improvements of this form are also even more drastic
when one considers statistical modeling of such tumor shapes. The presented examples thus
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support our proposal for the use of elastic shape analysis of GBM tumors for association
with patient survival and genomic variables.
2.2 Statistical summaries of tumor shapes
Hereafter, our analyses focus on the shape space S and the distance dS . However, we
illustrate the resulting differences in the statistical summaries under nonelastic and elastic
shape analysis. We define and illustrate computations of a mean tumor shape and co-
variance of a sample of tumor shapes, both defined with respect to dS . Consequently, we
demonstrate how sPCA can be applied to explore and visualize the directions of variation
in tumor shape based on patient-level information. Identifying such directions can be useful
in understanding the most likely deformations of the tumor shape, and can be potentially
used to monitor the disease and for targeted therapeutic interventions.
2.2.1 Mean and covariance
Under the SRVF framework, the shape space S is a (quotient space of a) nonlinear sub-
manifold of the Hilbert sphere, which is equipped with a Riemannian structure under the
L2 metric. We first introduce some notation. Let q1, q2 ∈ C be the SRVFs of two tumor
pre-shapes, and v ∈ Tq1(C) denote an element of the tangent space to C at q1. Then, the
maps q2 7→ v = exp−1q1 (q2) ∈ Tq1(C) and v 7→ q2 = expq1(v) ∈ C are the exponential and in-
verse exponential maps, respectively. These are not available analytically for the pre-shape
space of closed curves; algorithms for computing these quantities (Srivastava et al., 2011)
are similar to the technique for finding geodesics.
Let {β1, β2, . . . , βn} denote a sample of given tumor contours, and {q1, q2, . . . , qn} be
their corresponding SRVFs. Then, the Karcher (Frechet) mean tumor shape is defined as
[q¯] = argmin
[q]∈S
n∑
i=1
dS([q], [qi])2.
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A gradient-based approach for finding this mean is provided in Le (2001) and Dryden and
Mardia (1998), and is omitted here for brevity. The Karcher mean is actually an entire
equivalence class of curves. For the remainder of our analysis, we select one element of this
class q¯ ∈ [q¯]. The general computation of the covariance around the estimated shape mean
is as follows. Let vi = exp
−1
q¯ (q
∗
i ), i = 1, 2, . . . , n denote the shooting vectors from the mean
shape to each of the shapes in the given data. This first involves an optimal rotation O∗ and
optimal reparameterization γ∗ of each qi, resulting in q∗i = (O
∗q, γ∗), to register it to the
mean shape q¯. Then, the covariance kernel can be defined as a function Kq : S1 × S1 → R
given by Kq(ω, τ) = (1/(n− 1))
∑n
i=1 〈〈vi(ω), vi(τ)〉〉. In practice, since the curves have to
be sampled with a finite number of points, say m, the resulting covariance matrices are
finite-dimensional. Often, the observation size n is much less than m and, consequently, n
controls the degree of variability in the stochastic model. A comparison of elastic (allowing
optimal non-uniform spacing of points) and nonelastic (uniform spacing of points) averages
for the T1-weighted post-contrast and T2-weighted FLAIR GBM tumor shapes is provided
in Section 2 of the Supplementary Material. The elastic method is better at summarizing
the shapes of GBM tumors as it provides averages that have sharp geometric features.
2.2.2 Shape-based principal component analysis
We explore dominant directions of variation in a sample of tumor shapes with an efficient
basis for T[q¯](S) using traditional PCA as follows. Let V ∈ R2m×n be the observed tangent
data matrix with n observations and m sample points in R2 on each tangent, i.e., each
column of V is vi = exp
−1
q¯ (q
∗
i ), i = 1, 2, . . . , n, stacked into a long vector. Let K ∈
R2m×2m be the resulting covariance matrix and let K = UΣUT be its SVD. The submatrix
formed by the first r columns of U , called U˜ , spans the r-dimensional principal subspace
of the observed shapes and provides the observations of the principal coefficients as C =
U˜TV ∈ Rr×n. Thus, each original tumor shape can be represented using a finite set of
principal coefficients acting as Euclidean coordinates. These coefficients can then be used
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in a survival model for prediction as shown later.
A comparison of elastic versus nonelastic sPCA is provided in Section 2 of the Sup-
plementary Material. Elastic sPCA provides a more natural representation of variability
in the given dataset. We also compute the overall variance for each sPCA model as 7.86
(elastic) and 12.74 (nonelastic) for T1-weighted post-contrast images, and 13.43 (elastic)
and 27.68 (nonelastic) for T2-weighted FLAIR images. The elastic models are much more
compact, and thus provide a more efficient Euclidean representation of the tumor shapes
in terms of the principal coefficients.
2.2.3 Context-based simulation of tumor shapes
The exponential and inverse exponential maps provide tools to generate random tumor
shapes using the principal directions of shape variability obtained from sPCA. Figure ??
presents five randomly generated tumor shapes based on elastic sPCA of the GBM tumors
extracted from T1-weighted post-contrast and T2-weighted FLAIR images. Recall that
the SVD of the covariance matrix is given by K = UΣUT . Then, a random shape can
be obtained as follows. Suppose σi and ui are the ith diagonal element of Σ and the ith
column vector of U , respectively. Generate a random vector s =
∑κ
i=1
√
σiZiui, where
Zi are iid standard normal random variables and κ is the number of non-zero diagonal
elements of Σ. The random vector s is an element of the tangent space of the mean tumor
shape T[q¯](S). The random tumor shape is obtained by mapping s to a point q using
the exponential map. The resulting shape is a random sample from the wrapped normal
distribution. Indeed, different distributions on Z can be used to generate a large class
of tumor shapes. We provide several examples of randomly generated tumor shapes in
Section 2 of the Supplementary Material. These random samples appear quite realistic
when compared to real tumor shapes in the GBM dataset.
Next, we study the quality of the elastic sPCA model by measuring the leave-one-out
shape reconstruction error for each modality. This test is performed as follows. We first
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Elastic Mean Standard Deviation Median Median Absolute Deviation
T1 0.0097 0.0086 0.0071 0.0055
T2 0.0249 0.0199 0.0195 0.0150
Nonelastic
T1 0.0138 0.0113 0.0108 0.0075
T2 0.0361 0.0293 0.0261 0.0220
Table 1: Summary statistics of the tumor shape reconstruction error E for the T1-weighted post-contrast
(T1) and the T2-weighted FLAIR (T2) imaging modalities.
form a dataset of size n − 1 by leaving out the test tumor contour, say qi, and estimate
the mean shape q¯ and PC basis U as previously described. Then, we compute two vectors
in the tangent space T[q¯](S): (1) vi = exp−1q¯ (q∗i ) or the true tangent vector corresponding
to the shape q∗i (registered to q¯), and (2) v˜i =
∑n−2
j=1 〈〈vi, Uj〉〉Uj or the reconstruction
of vi using the elastic PC basis. The leave-one-out reconstruction error for shape i is
measured using E(i) = ‖vi − v˜i‖2. We repeat this for all tumor contours in the dataset,
i.e., i = 1, . . . , 63. We repeat this procedure for the nonelastic framework and report all
results of this simulation in Table 1. First, it is clear that the elastic sPCA model is better
at reconstructing GBM tumor shapes than its nonelastic counterpart. Again, this suggests
that elastic shape analysis is a more appropriate framework for studying GBM tumors. The
elastic sPCA model estimated for the T1-weighted post-contrast tumor shapes is better at
leave-one-out reconstruction (than the T2-weighted FLAIR elastic sPCA model) and thus
provides a more faithful representation of the given tumor shapes. Nonetheless, for both
modalities, the elastic sPCA models result in very low reconstruction errors. The maximum
observed reconstruction error for the T1-weighted post-contrast tumor shapes is only 0.0446
or 1.81% of the maximum possible error ((pi/2)2); the median reconstruction error for the
T2-weighted FLAIR tumor shapes is only 0.0955 or 3.87% of the maximum possible error.
The overall variability is also low in both cases for the elastic approach.
Figure 6 displays three leave-one-out elastic tumor shape reconstruction examples for
each imaging modality: the reconstructions with smallest (left), median (middle) and
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T1
T2
Figure 6: Three examples (left=minimum error, middle=median error, right=maximum error) of leave-
one-out tumor shape reconstructions using sPCA models estimated using the T1-weighted post-contrast
(row labeled T1) and T2-weighted FLAIR (row labeled T2) modalities. The true tumor shape is shown in
blue while the reconstruction is given in red.
largest (right) error. Reconstructions with minimum and median error for both modal-
ities are visually very good; reconstructions with maximum error show some larger errors
in parts of the tumors. Nonetheless, even these reconstructions follow the general shape of
the true tumor shapes.
3 Radiologic imaging in Glioblastoma
The elastic framework for analyzing tumor shapes allows one to perform a variety of estima-
tion and inferential statistical tasks. In particular, sPCA of tumors provides the possibility
of devising methods based on principal coefficients, which can be profitably viewed as Eu-
clidean features or summaries of the tumor shape for inclusion in regression models. Using
a dataset of MRIs of GBM brain tumors, we applied clustering, two-sample testing, and
survival modeling to illustrate the advantages associated with the elastic representation of
tumor shapes and the related geometric framework in the context of assessing patient sur-
vival and association with genomic/clinical variables. Note that from here on, we perform
statistical analysis via the elastic framework only. We begin with a detailed description of
the GBM dataset.
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3.1 Description of dataset
GBM, the most common malignant brain tumor found in adults, is a morphologically het-
erogeneous disease. Despite recent medical advancements, the prognosis for most patients
with GBM is extremely poor. In the United States alone, 12 thousand new cases are being
diagnosed every year1, among which less than 10% survive 5 years after diagnosis (Tutt,
2011). The median survival time for patients diagnosed with GBM is approximately 12
months (McLendon et al., 2008). Biological features that differentiate GBM from any other
grade of tumor include hypoxia and pseudopalisading necrosis, and proliferation of blood
vessels near the tumor.
For our study, we collated MR images with linked genomic and clinical data from 63
patients who consented under The Cancer Genome Atlas protocols2. The data from pre-
surgical T1-weighted post-contrast and T2-weighted FLAIR MRIs for these patients were
obtained from The Cancer Imaging Archive3. The dataset comprising survival times, and
clinical and genomic variables for these patients was obtained from cBioPortal4.
The imaging dataset is a subset of a larger patient cohort that contains information
on the linked clinical and genomic variables. For clinical variables, we used the survival
times of the patients and Karnofsky performance scores (KPSs) (Karnofsky and Burchenal,
1949). KPS indicates the ability of cancer patients to perform simple tasks (Crooks et al.,
1991) and is widely used to assess quality of life during disease diagnosis and treatment.
The demographic variables corresponding to the clinical covariates in this dataset are pre-
sented in Section 1 of the Supplementary Material. Recent investigations have identified
four different subtypes of GBM: classical, mesenchymal, neural and proneural, each
of which is characterized by different molecular alterations (Verhaak et al., 2010). We
also curated the information about these subtypes of GBM and some well-characterized
1http://www.abta.org/about-us/news/brain-tumor-statistics/
2http://cancergenome.nih.gov/
3http://www.cancerimagingarchive.net/
4http://www.cbioportal.org/
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Cumulative Variance T1 T2
Cluster 1 5.51 10.23
Cluster 2 14.74 17.95
Table 2: Cumulative variance of the cluster-wise sPCA models for the T1-weighted post-contrast (T1)
and T2-weighted FLAIR (T2) tumor data.
GBM driver genes (Frattini et al., 2013): DDIT3, EGFR, KIT, MDM4, PDGFRA, PIK3CA
and PTEN. Biologically, a gene is known as a driver gene when there is a mutation along
with DNA-level changes (amplifications or deletions). The full tumor volumes from T1-
weighted post-contrast and T2-weighted FLAIR MRIs were also recorded for each patient.
Pre-processing of images including details of segmentation, and a more detailed descrip-
tion of the clinical and genomic covariates can be found in Section 1 of the Supplementary
Material.
3.2 Clustering of GBM tumor shapes
As a first unsupervised task, we performed hierarchical clustering of T1-weighted post-
contrast and T2-weighted FLAIR tumor shapes using the elastic shape metric. We first
calculated the pairwise distance matrix and then used complete linkage to separate the
shapes into two clusters (motivated by short vs. long survival and supported by cluster
visualization, see bottom panel of Figure 7) for each modality. To better visualize the
variability in each cluster, we performed cluster-wise sPCA and plotted the three principal
directions of variation in each cluster for the T1-weighted post-contrast and T2-weighted
FLAIR modalities in Figure 7. We also report the cumulative variance in each cluster for
both modalities in Table 2. In both cases, the variance in cluster 1 is much smaller than
the variance in cluster 2. This can also be seen in the principal directions of variation; the
shapes shown along cluster 1 directions (including the mean shape) are much smoother (or
less ‘wiggly’) and circular.
We present a multidimensional scaling plot of the data in the bottom panel of Figure 7.
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T1 Cluster 1 T1 Cluster 2
T2 Cluster 1 T2 Cluster 2
T1 MDS T2 MDS
−0.2 0 0.2 0.4 0.6−0.4
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Figure 7: Cluster-wise principal directions of variation for T1-weighted post-contrast (top) and T2-
weighted FLAIR tumor shapes (middle). The mean in marked in red. Bottom: Multidimensional scaling
plots of the T1-weighted post-contrast and T2-weighted FLAIR tumor shape data (cluster 1=blue, cluster
2=red).
This plot confirms that cluster 2 is much more variable than cluster 1. Furthermore, the
separability of the clusters is very good for both modalities suggesting that the choice of two
clusters is appropriate in this setting. In Table 3, we provide the mean and median survival
times associated with the clusters, computed using tumor shape data in each modality. We
see that the mean and median survival times are higher in cluster 1, which contains much
lower cumulative variance. This suggests that cluster 1 is more homogeneous, which is
associated with longer survival times. Cluster 2 is more heterogeneous and is associated
with shorter survival times. This can also be attributed to the general morphological
structure of tumors in the two clusters. The tumors in cluster 1 are often smoother and
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Survival (in months) T1 Mean T1 Median T2 Mean T2 Median
Cluster 1 18.8 14.4 18.2 14.2
Cluster 2 12.0 10.8 16.3 13.3
Difference 6.8 3.6 1.9 0.9
Table 3: Summaries of cluster-wise survival for the T1-weighted post-contrast (T1) and T2-weighted
FLAIR (T2) tumor data.
more spherical than those in cluster 2, which are more irregular. It is this irregularity
and non-smoothness that is indicative of a more severe and infiltrative tumor with blurred
margins and as a result, shorter survival times. Second, the mean difference in survival
times between cluster 1 and cluster 2 computed using T1-weighted post-contrast tumor
shapes is 6.8 months. This is a large number considering the median survival time in GBM
is only approximately 12 months.
3.2.1 Cluster validation via enrichment
We use the concept of Bayesian cluster enrichment to study the association between the
computed clusters, the tumor subtypes and other genomic covariates. In this approach,
we want to compare the relative occurrence of a specific dichotomous covariate (with label
0 for no occurrence and 1 for occurrence) across the two clusters. To develop a Bayesian
model for this purpose, let θ1 ∈ [0, 1] denote the true proportion of 1s in cluster 1; let
y1 denote the observed number of 1s in cluster 1. Similarly, let θ2 ∈ [0, 1] denote the
true proportion of 0s in cluster 1 and y2 denote the observed number of 0s in cluster 1.
Then, y1 ∼ Binomial(n1, θ1) and y2 ∼ Binomial(n2, θ2), where n1 is the total number of
1s and n2 is the total number of 0s. Consider a Uniform(0, 1) (Beta(1, 1)) prior on the
true proportions θ1 and θ2. Since the Beta distribution is conjugate for the Binomial, the
posterior distribution is of the same family as the prior; the resulting posterior distributions
for θ1 and θ2 are given by piθ1(θ1|y1, n1) ∼ Beta(y1 + 1, n1 − y1 + 1) and piθ2(θ2|y2, n2) ∼
Beta(y2 +1, n2−y2 +1). We generate a large number of samples from the two posteriors piθ1
and piθ2 and approximate the true probability P (θ1 > θ2) using a Monte Carlo method. We
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T1 T2
Figure 8: Enrichment plots for the T1-weighted post-contrast (T1) and T2-weighted FLAIR (T2) modal-
ities: (a) classical; (b) mesenchymal; (c) proneural; (d) EGFR; (e) MDM4; (f) PDGFRA; (g) PIK3CA;
(h) PTEN. The red lines indicate the 0.75 and 0.25 cutoffs for ‘high’ enrichment in cluster 1 (blue) and
cluster 2 (green), respectively.
refer to this approximate quantity as the enrichment probability. The intuition behind this
approach is as follows. If the computed clusters are not associated with the dichotomous
covariate of interest, the resulting posteriors for θ1 and θ2 should be very similar. This in
turn results in a Monte Carlo estimate of P (θ1 > θ2) close to 0.5, or no enrichment. On
the other hand, when the two posteriors are drastically different, the Monte Carlo estimate
of P (θ1 > θ2) would be either very close to 1 (if y1 is much larger than y2) or 0 (if y1 is
much smaller than y2). These two scenarios constitute high enrichment of the covariate in
one of the two computed clusters (a given covariate can be enriched in only one cluster at
a time).
We present enrichment plots in Figure 8. Each plot shows the enrichment probabilities
as a line plot with high and low cutoffs in the form of horizontal lines at 0.75 and 0.25. We
note the following trends from the enrichment plots. The classical and mesenchymal tumor
subtypes are enriched in cluster 1 for both modalities. The proneural tumor subtype is
enriched in cluster 2 for the T2-weighted FLAIR modality. Interestingly, the mesenchymal
subtype, a very aggressive form of GBM, was enriched in the cluster with higher survival.
However, upon closer examination, there was an equal number of mesenchymal and non-
mesenchymal subtypes in cluster 1 for both modalities (the enrichment probability was
mostly driven by the arrangement in cluster 2). Furthermore, the patients in cluster 1 with
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the mesenchymal subtype had lower survival than their nonmesenchymal counterparts (by
approximately 1.5 months).
The enrichment plots for both imaging modalities display results consistent with some
of the well-characterized genomic signatures in GBM. We note the following strong asso-
ciations between tumor subtypes and driver gene mutations that have also been found in
other studies (McNamara et al., 2013; Verhaak et al., 2010):
1. Proneural subtype and PDGFRA mutation (in T2-weighted FLAIR);
2. Classical and mesenchymal subtypes and EGFR mutation (in T2-weighted FLAIR).
EGFR mutation is a common molecular signature of GBM. It promotes proliferation of the
tumor, which is associated with classical and mesenchymal subtypes (Fischer and Aldape,
2010). PDGFRA also plays an important role in cell proliferation and migration, and
angiogenesis. Unlike EGFR, this gene was found to be mutated in high amounts in the
proneural subtype of GBM tumors only (Verhaak et al., 2010).
3.3 Permutation test for difference in tumor shape means
The distance dS between two tumor shapes opens up the possibility of a distance-based
nonparametric two-sample test for differences in mean tumor shapes. To ascertain the
association between tumor shapes and survival times of GBM patients, we dichotomize
the data based on four different survival cutoffs examined in the literature (Nebert, 2000;
Affronti et al., 2009; Mazurowski et al., 2013): 12, 13, 14 and 15 months. Under the null
hypothesis that the two groups have equal mean shapes, a permutation test analogous to
the case of landmark-based shape analysis (Dryden and Mardia, 1998) can be constructed
under no assumptions on the distributions of the two groups. For each cutoff, we calculate
the test statistic, which is the shape distance dS between the Karcher mean estimates for
the two groups based on the given data. The distribution of this test statistic under the
null hypothesis is not easily determined.
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Survival Cutoff T1 p-value T2 p-value
12 months 0.511 0.134
13 months 0.039 0.426
14 months 0.712 <0.001
15 months 0.841 <0.001
Table 4: Permutation test results for T1-weighted post-contrast (T1) and T2-weighted FLAIR (T2) tumor
shapes.
Thus, we employ a permutation test by combining the shapes from both samples. Note
that the generated survival labels are exchangeable under the null hypothesis. We use 1000
random permutations of the labels to generate the distribution of the test statistic. The
resulting p-values for the T1-weighted post-contrast and T2-weighted FLAIR modalities,
and all of the cutoffs, are presented in Table 4. Based on our test statistic, there is a
significant difference between T1-weighted post-contrast mean tumor shapes at the 0.05
level only at the 13-month cutoff. For the T2-weighted FLAIR tumor shapes, there is
a highly significant shape mean difference for the 14- and 15-month cutoffs. The results
clearly depend on the choice of the cutoff; nevertheless, this result provides support for our
hypothesis that tumor shape features can be useful in survival analysis in GBM studies.
We only use the mean shape information in this hypothesis test, although we expect that
the covariance information is also useful. We demonstrate how that can be achieved using
a principal coefficient representation of tumor shapes in subsequent survival modeling.
3.4 Survival model adjusted for tumor shape
Next, we ascertain the utility of augmenting clinical and genetic information with imaging
information when modeling survival probabilities of GBM patients. In particular, we in-
vestigate the association between the shape of a tumor and survival times (with censoring),
in the presence of genetic and clinical covariates, using the geometry-based elastic shape
methodology. Upon performing sPCA in the shape space S, each tumor contour shape is
represented in the principal directions of the variation basis using its principal coefficients,
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which can be used as predictors in a survival model. Geodesic paths constructed using
principal shooting vectors allow for the possibility of traversing the principal directions of
shape variation and monitoring changes in the shape of a tumor. It is customary to choose
a handful of principal directions that explain most of the shape variability; however, since
S is infinite-dimensional, and it is unclear as to how one can interpret the directions in the
context of tumor shapes, we propose to use all available directions so as to capture maxi-
mal information from the data. Indeed, it may very well be that a direction corresponding
to a small (in magnitude) eigenvalue represents a physiologically important tumor shape
deformation. In order to incorporate all information from the images, we perform separate
sPCA on tumors obtained from both T1-weighted post-contrast and T2-weighted FLAIR
MRIs, and collate the principal coefficients from each imaging modality. Employing all
available shape principal coefficients translates to a large number of imaging-based shape
predictors in a potential survival model necessitating dimension reduction through variable
selection.
To assess whether incorporating imaging covariates, through principal tumor shape
coefficients, improves discriminatory power of the survival model, we compare three nested
models: (1) M1, a model with a set of clinical covariates C ; (2) M2, a model with clinical
and a set of genetic covariates G ; and (3) M3, a model with clinical, genetic and a set of
imaging covariates I in the form of shape principal coefficients; note that M1 ⊂M2 ⊂M3
where A ⊂ B denotes that model A is nested within model B.
The clinical covariate of KPS contains a few missing values; therefore, we impute a
value of 80 for those cases as advised by Gutman et al. (2013). A proportional hazards
model (Cox, 1972), hereafter referred to as the Cox model, is used as the de facto model
underlying M1,M2 and M3, modeling the survival times of the patients in the presence
of the clinical, genetic and imaging predictors. Note that M1 := Cox model with C ,
M2 := Cox model with C ∪G , and M3 := Cox model with C ∪G ∪ I . Importantly, model
M3, with a large number of tumor shape principal coefficients as predictors (62 each for
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T1-weighted post-contrast and T2-weighted FLAIR), is fitted to the data by penalizing the
negative log-likelihood using a lasso penalty. Furthermore, a leave-one-out cross-validation
strategy is employed to evaluate the model. Specifically, if η is the vector of coefficients, then
M3 is fit by solving the optimization problem minη
[
- log-partial likelihood of M3
]
+λ|η|1,
where |η|1 is the L1 norm of η. We use the R package glmnet by Friedman et al. (2011)
for our implementation of model M3 with leave-one-out cross-validation. The set I is
consequently redefined to contain only the principal coefficients with non-zero regression
coefficients obtained from this lasso regression.
3.4.1 Significant directions of shape variation and other results
Next, we focus on the results of fitting the three models. Using the lasso penalty for
model M3, we first identify the principal tumor shape coefficients with non-zero regression
coefficients, owing to the lack of a general accepted way of testing for significance within
the lasso framework (see recent work by Lockhart et al. (2014)). We uncover six principal
directions of variation from T1-weighted post-contrast tumor shapes and five from T2-
weighted FLAIR tumor shapes, when adjusted for the presence of predictors in C and
G . The 11 coefficients comprise the operative new set I . We plot deformations of the
Karcher mean tumor shape by following the vector field along the geodesic in the directions
represented by the significant principal coefficients in the survival model. Such plots can
potentially be used by neuroradiologists to visualize and make qualitative statements about
deviations from the mean shape relating to increased or decreased chances of survival, when
adjusting for the presence of clinical and genetic factors. Figure 9 illustrates this in the
direction of a decreased chance of survival for T2-weighted FLAIR images; the directions for
T1-weighted post-contrast images can found in Section 3 of the Supplementary Material.
We note that the shapes become more irregular as one traverses the significant principal
directions in the direction of a decreased chance of survival. The higher principal directions
show global deformations that introduce a high level of non-smoothness while the lower
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Figure 9: Different displays for the significant principal directions of variation (low to high variance
from top to bottom) in T2-weighted FLAIR tumor shapes. (a) Tumor shapes obtained as one follows the
deformation vector field along a geodesic in the direction of decreased chance of survival for t = 0 (Karcher
mean, red), and t = 2, 4, 6. (b) Pointwise magnitude of the principal deformation vector field displayed
on the Karcher mean shape. (c) Principal deformation vector field displayed on the Karcher mean shape.
principal directions account for local roughness of the shapes. The global deformations are
especially indicative of a protrusion of the tumors into neighboring structures.
Results from fitting the three Cox models are given in Table 5. Gutman et al. (2013)
found significant association between the clinical covariate KPS and survival time, adjusting
for the presence of other numerical radiological features/summaries; this agrees with our
results for all three models. Although the KPS score is measured on a scale of 0-100, the only
distinct values in our dataset were 60, 80 and 100 along with missing values for 12 patients.
As a measure of the ability to perform activities of daily living, the KPS scores only
influence the survival time indirectly, and in this dataset, they complement the influence of
the tumor shape principal coefficients. Since tumor volume was recorded for each patient
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Model Predictors C-index 1 C-index 2
Significant at 5% Level
M1 Age, KPS 0.641 0.652
Clinical
M2 Age, KPS 0.722 0.728
Clinical+Genetic DDIT3, PIKC3A
M3 Age, KPS, DDIT3 0.859 0.841
Clinical+Genetic+Imaging 11 PC shape coefficients
Table 5: Results from fitting Cox models M1, M2 and M3. Predictors significant at the 5% level are
tabulated, and the two concordance indices (C-index 1 = (Harrell et al., 1982), C-index 2 = (Go¨men and
Heller, 2005)) are reported.
from T1-weighted post-contrast and T2-weighted FLAIR images, we considered the shapes
of tumor outlines rather than shapes and sizes. The size of the tumor was included in the
model as a separate covariate through the tumor volume. It is known that tumors with
EGFR mutations are larger than tumors with other mutations (Hatanpaa et al., 2010). In our
analyses, EGFR and tumor volumes from both T1-weighted post-contrast and T2-weighted
FLAIR images were not found to significantly correlate with survival time in the presence
of tumor shape information. This finding is at odds with that of Gutman et al. (2013)
where lesion size was used. It is known that older patients with GBM show high EGFR
amplification. However, the variable EGFR informs us only if a mutation has occurred, not
amplification. The age of a patient diagnosed with GBM is known to influence the survival
time (Weller and Wick, 2011). Older age is typically used as a surrogate marker for change
in the biology of GBM. The mean age in our dataset was 56.33 years; the variable Age
appeared to have significant correlation with survival time in all three models, and the
inclusion of tumor shape information did not alter that.
The discriminatory power of models M1, M2 and M3 are compared using their con-
cordance indices (C-indices), which are defined as the proportion of all pairs of patients
whose predicted survival times are correctly ordered among all patients that can actually
be ordered. For comparison purposes, we use the C-index proposed by Harrell et al. (1982,
1984), and another version of it based on a U-statistic (Go¨men and Heller, 2005). The
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C-indices (obtained through both methods) for the model M3 are significantly higher than
the C-indices for M2 and M1. This indicates a clear benefit in incorporating imaging pre-
dictors in the form of tumor shape principal coefficients into a survival model in order to
obtain good discriminatory power. The Kaplan–Meier estimates of the survival functions
for the three models, along with a detailed description, are provided in Section 3 of the
Supplementary Material.
In summary, amongst the driver genes known to be significant in GBM studies, only
DDIT3 appears to have a significant correlation with the survival time of a patient when
adjusted for the effect of tumor shape. Mutation of the driver-gene DDIT3 appears to be
associated with low survival probability (see Figure 5 in the Supplementary Material); it is
known to indirectly regulate the glioma pathway through unregulated genes. Our analyses
indicate that the shape of the tumor captures sufficient information about the individual
relationships between each of the driver genes and survival time. A deeper study of the
relationships between the shape of the tumor and driver genes is well worth exploring.
4 Discussion and future work
The use of shape analysis in medical imaging has been proposed before in other disease
domains; we refer the reader to Chapter 17 of the edited volume by Tofts (2003) and ref-
erences within, for a good review. The shape of specific anatomical structures in the brain
has been successfully used in multiple sclerosis studies by Goldberg-Zimring et al. (1998),
who, based the analysis of the shape on a few shape indices of the lesion. Landmark-based
techniques using Procrustes averaging were used to study schizophrenia by DeQuardo et al.
(1996). However, landmark and descriptor-based methods are not directly applicable to
oncology due to multiple issues mentioned in this paper. In this work, we provide a com-
prehensive, Riemannian geometric solution to this problem that provides tools for various
statistical analyses of tumor shapes. The benefits of this framework are clear: (1) it pro-
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vides an elastic metric to measure interpretable shape deformations, (2) it defines a formal
mathematical and statistical framework, and (3) it provides tools for shape alignment,
comparison, summarization, clustering, classification, hypothesis testing and other tasks.
We demonstrate these benefits through a detailed study of tumor shapes in the context of
GBM. The proposed method can be readily extended to any cancer and/or other imaging
modalities with similar data characteristics and scientific questions.
The focus of this article is on 2D tumor shapes obtained from the segmented tumor
of a single axial slice of the brain with largest tumor area. The influence of the location
and anisotropic nature of the white matter tracts on the shape of the tumor can be better
assessed with 3D shape analysis, which is currently in progress. The geometric framework
presented in this paper allows for the extension to 3D shapes (square-root normal fields
(Jermyn et al., 2012)), but visualization of principal directions of variation becomes more
difficult. Except for the work of Goldberg-Zimring et al. (2005) who used spherical harmonic
functions to model the 3D shape of a tumor (akin to nonelastic analysis of tumor shapes),
there is a lack of progress in this direction.
One way to view the proposed survival model is within the context offered by regression
with functional predictors. The parametric closed curve representing a tumor shape pre-
dictor can be viewed as an element of the pre-shape space C, which is the Hilbert space S∞.
Nevertheless, S∞ is a submanifold of L2(S1) and not a vector space; current approaches
with functional predictors using basis representations of the tumor shape or the coefficient
function, or both, are hence inapplicable (see (Morris, 2015) for a detailed review).
The geometric framework used in this article enables us to perform PCA on the space
of tumor shapes under a Riemannian metric. The physiological interpretation of the prin-
cipal directions, however, is unclear and much work remains to be done in this direction.
Construction of a set of basis functions for the tangent space of a tumor shape that cap-
tures the biologically relevant deformations of the shape would be particularly useful; this
requires significant input from clinicians in the form of prior shape information. In Figure
34
9, the deformations observed in the tumor shape as we move away from the mean tumor
shape along the direction of decreased survival are striking; the shape appears to become
more spiculated, which is consistent with the heuristic understanding of the seriousness
of an irregularly shaped tumor. The visualization afforded within our framework, in our
opinion, can profitably be used by neuroradiologists for initial non-invasive diagnoses.
Applying the survival model M3 to the GBM dataset, we uncover several potentially
interesting relationships between the shape of the tumor (expressed through the principal
coefficients) and driver genes. This merits further consideration, and the implementation
of our methods on other GBM datasets would offer more insight. Biological validation of
the correlations between the two can significantly impact targeted personalized treatment
strategies for GBM patients. Importantly, prognostic and predictive biomarkers of the
transition time from a low-grade glioma to a malignant one can be determined.
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